for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG (ADR)

NVS.N

Latest Trade

90.53USD

Change

0.13(+0.14%)

Volume

229,205

Today's Range

90.25

 - 

90.69

52 Week Range

74.97

 - 

96.31

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
90.40
Open
90.28
Volume
229,205
3M AVG Volume
36.10
Today's High
90.69
Today's Low
90.25
52 Week High
96.31
52 Week Low
74.97
Shares Out (MIL)
2,527.37
Market Cap (MIL)
227,859.60
Forward P/E
17.23
Dividend (Yield %)
3.14

Next Event

Novartis AG at Jefferies London Healthcare Conference

Latest Developments

More

FDA Says Approves Novartis' Sickle Cell Disease Treatment Adakveo 100 Mg/10 Ml Injection

Novartis Says New Medicine Adakveo® (Crizanlizumab) Approved By FDA

Novartis Gets Positive CHMP Opinion For Mayzent For Treatment Of Adult Patients With Active SPMS

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG (ADR)

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Alex Krauer

Honorary Chairman of the Board

Daniel L. Vasella

Honorary Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Independent Non-Executive Vice Chairman of the Board

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

48.5K

2017

49.1K

2018

51.9K

2019(E)

47.8K
EPS (USD)

2016

4.710

2017

4.860

2018

5.150

2019(E)

5.242
Price To Earnings (TTM)
29.15
Price To Sales (TTM)
4.60
Price To Book (MRQ)
3.90
Price To Cash Flow (TTM)
17.77
Total Debt To Equity (MRQ)
57.34
LT Debt To Equity (MRQ)
41.57
Return on Investment (TTM)
7.13
Return on Equity (TTM)
5.57

Latest News

Latest News

Swiss eyecare company Alcon posts another loss, announces revamp

Swiss-listed eyecare company Alcon reported another quarterly loss, specified its profit outlook, boosted projections for the cost of its spinoff from Novartis and announced a $300 million restructuring program.

Novartis eyes Medicines Co to boost cardio franchise: report

Novartis <NOVN.S> is considering an offer for U.S. biotechnology firm The Medicines Co <MDCO.O>, Bloomberg reported on Tuesday, a deal that could broaden the Swiss drugmaker's cabinet of heart medicines and shore up growth threatened by patent expirations.

Novartis declines comment on reported interest in Medicines Co

Swiss drugmaker Novartis on Tuesday declined to comment on a media report that it is considering an offer for U.S. biotechnology company The Medicines Co.

Novartis switches gears in Shanghai from research to drug development

Novartis is exiting drug discovery at its Shanghai site and shifting its focus to drug development, saying accelerating approvals in China are pushing the Swiss company to dedicate the operation's resources to getting its medicines to market.

Novartis shifts Shanghai's focus from research to early development

Novartis is halting early-stage research in Shanghai and shifting the site's focus to commercial development three years after the Swiss drugmaker christened the new $1 billion campus as its Chinese drug discovery hub.

BRIEF-Novartis Says Paragon-HF Analyses Suggest Entresto Benefit Beyond HFREF

* NOVARTIS PARAGON-HF ANALYSES SUGGEST ENTRESTO® BENEFIT BEYOND HFREF

Novartis sickle-cell drug gets U.S. FDA approval

(The Nov 16 story corrects to clarify in second graph that patients will be infused by a healthcare provider.)

BRIEF-Novartis Says New Medicine Adakveo® (Crizanlizumab) Approved By FDA

* REG-NEW NOVARTIS MEDICINE ADAKVEO® (CRIZANLIZUMAB) APPROVED BY FDA TO REDUCE FREQUENCY OF PAIN CRISES IN INDIVIDUALS LIVING WITH SICKLE CELL DISEASE

BRIEF-Novartis Gets Positive CHMP Opinion For Mayzent For Treatment Of Adult Patients With Active SPMS

* NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR MAYZENT® (SIPONIMOD) FOR THE TREATMENT OF ADULT PATIENTS WITH ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

BRIEF-Novartis cites positive data for Cosentyx in axial spondyloarthritis

* NEW NOVARTIS PREVENT DATA SHOW COSENTYX DELIVERS EARLY RELIEF IN AXIAL SPONDYLOARTHRITIS

Roche drug for spinal muscular atrophy hits target in late-stage trial

Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function in a key study.

Roche sets sights on Novartis, Biogen as SMA trial hits target

Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study.

Novartis buys Aspen's Japanese generic unit for up to 400 million euros

Novartis <NOVN.S> is buying the Japanese generics unit of South Africa's Aspen Pharmacare <APNJ.J> in a deal worth up to 400 million euros ($440.80 million) to expand in the world's third-biggest drug market, the Swiss drugmaker said on Monday.

South Africa's Aspen to sell Japan operations to Novartis unit

Aspen Pharmacare Holdings agreed to sell its Japanese operations to Novartis' Sandoz for up to 400 million euros ($440.80 million) through a unit as it looks to cut debt, the South African drugmaker said on Monday.

Novartis's Sandoz generics unit buying Aspen's Japanese operations

Novartis' Sandoz generic drug unit is buying Aspen's Japanese operations for an initial payment of 300 million euros ($330.60 million) to expand in the world's third-biggest generic medicines market, the Swiss drugmaker said on Monday.

Novartis gets U.S. nod for long-delayed Amgen copycat

Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's $4 billion seller Neulasta drug, helping the Swiss drugmaker in its uphill battle to sell copies of rivals' blockbusters in the world's top drug market.

Novartis arthritis drug falls short in challenge to global bestseller

Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis.

Novartis arthritis drug fails to prove it is significantly better than rival

A clinical trial of Novartis's Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said on Friday.

Novartis' Zolgensma study halted by FDA amid safety questions

U.S. regulators have halted a trial of Novartis's Zolgensma treatment after an animal study raised safety concerns, the company said on Wednesday, in a setback for the drugmaker's plan to expand its use to older patients.

BRIEF-Novartis Says FDA Placed Partial Hold On Avxs-101 Intrathecal Trials For SMA Patients

* FDA PLACED A PARTIAL HOLD ON AVXS-101 INTRATHECAL CLINICAL TRIALS FOR SMA PATIENTS BASED ON FINDINGS IN A SMALL PRE-CLINICAL ANIMAL STUDY

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up